Akorn Inc (AKRX) 30.66 $AKRX Technical Analysis on Drugs

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Akorn Inc (AKRX) 30.66 $AKRX

Technical Analysis on Drugs - Generic Equities -- Akorn, Ironwood Pharma, Catalyst Pharma, and Pacira Pharma
PR Newswire - Fri Jun 10, 7:00AM CDT
On Thursday, June 09, 2016, the NASDAQ Composite ended the trading session at 4,958.62, down 0.32%; the Dow Jones Industrial Average edged 0.11% lower to finish at 17,985.19; and the S&P 500 closed at 2,115.48, down 0.17%. ActiveWallSt.com has initiated coverage on the following equities: Akorn Inc. (NASDAQ: AKRX), Ironwood Pharmaceuticals Inc. (NASDAQ: IRWD), Catalyst Pharmaceuticals Inc. (NASDAQ: CPRX), and Pacira Pharmaceuticals Inc. (NASDAQ: PCRX). Learn more about these stocks by accessing their free trade alerts at:
IRWD: 13.37 (+0.25), CPRX: 0.80 (+0.03), AKRX: 30.66 (+0.64), PCRX: 36.39 (+0.53)

Akorn Updates Form S-8 Status by Filing Form 10-Q's for First, Second and Third Quarters of 2015
GlobeNewswire - Thu Jun 02, 5:30AM CDT
Akorn, Inc. (Nasdaq:AKRX), a leading specialty generic pharmaceutical company, today announced that it has filed quarterly reports on Forms 10-Q with the Securities and Exchange Commission (SEC) for the quarters ended March 31, 2015, June 30, 2015 and September 30, 2015. The quarterly financial results that are included in the individual Forms 10-Q were previously filed by the Company in its comprehensive Form 10-K for the fiscal year 2015 that was filed with the SEC on May 10, 2016. The individual Forms 10-Q were filed solely in order to make effective the Company's Registration Statement on Form S-8, on which the Company's securities offered under its employee benefit plan are registered.
AKRX: 30.66 (+0.64)

Akorn to Present at Two Upcoming Investor Conferences
GlobeNewswire - Tue May 31, 7:30AM CDT
Akorn, Inc. (Nasdaq:AKRX), a leading specialty generic pharmaceutical company, today announced that management will be presenting at the Jefferies 2016 Healthcare Conference and William Blair 36th Annual Growth Stock Conference in June.
AKRX: 30.66 (+0.64)

SmarTrend Watching for Potential Rebound in Shares of Akorn After 2.24% Loss
Comtex SmarTrend(R) - Thu May 26, 2:05PM CDT
Akorn (NASDAQ:AKRX) traded in a range yesterday that spanned from a low of $29.37 to a high of $30.51. Yesterday, the shares fell 2.2%, which took the trading range below the 3-day low of $30.27 on volume of 1.0 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
AKRX: 30.66 (+0.64)

Akorn (AKRX) Shares March Higher, Can It Continue?
Zacks Equity Research - Zacks Investment Research - Thu May 19, 7:54AM CDT
As of late, it has definitely been a great time to be an investor in Akorn, Inc. (AKRX)
AKRX: 30.66 (+0.64)

Watch for Akorn to Potentially Pullback After Gaining 7.19% Yesterday
Comtex SmarTrend(R) - Tue May 17, 1:24PM CDT
Akorn (NASDAQ:AKRX) traded in a range yesterday that spanned from a low of $27.90 to a high of $30.39. Yesterday, the shares gained 7.2%, which took the trading range above the 3-day high of $28.19 on volume of 3.5 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
AKRX: 30.66 (+0.64)

Akorn meets 1Q profit forecasts
Automated Insights - Mon May 16, 4:03PM CDT
LAKE FOREST, Ill. (AP) _ Akorn Inc. (AKRX) on Monday reported first-quarter earnings of $41.9 million.
AKRX: 30.66 (+0.64)

SmarTrend Watching for Potential Pullback in Shares of Akorn After 14.34% Gain
Comtex SmarTrend(R) - Tue May 10, 3:26PM CDT
Akorn (NASDAQ:AKRX) traded in a range yesterday that spanned from a low of $24.43 to a high of $26.81. Yesterday, the shares gained 14.3%, which took the trading range above the 3-day high of $24.43 on volume of 2.8 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
AKRX: 30.66 (+0.64)

Teva's (TEVA) Stock Gains on Q1 Earnings & Revenue Beat
Arpita Dutt - Zacks Investment Research - Tue May 10, 6:18AM CDT
2016 is a transition year for Teva (TEVA) as it works on the integration of Actavis Generics and progresses with its branded pipeline.
AKRX: 30.66 (+0.64), TEVA: 50.89 (+0.37), AMPH: 16.80 (+0.14), NVS: 82.13 (+0.33)

Relypsa Soars 67% in Thursday Trading on Buyout Rumors
Arpita Dutt - Zacks Investment Research - Fri Apr 08, 8:50AM CDT
Relypsa (RLYP) shoots up on rumors that the company will be acquired.
AKRX: 30.66 (+0.64), RLYP: 20.17 (+0.57), AZN: 30.11 (unch), AMPH: 16.80 (+0.14)

3 Value Stocks Near 52-Week Lows Worth Buying
Sean Williams, The Motley Fool - Motley Fool - Thu Mar 24, 8:21AM CDT
Image source: Pixabay. While many companies' shares are rising past their fair values now, others are trading at potentially bargain prices. The difficulty with bargain shopping, though, is that you may be understandably hesitant to buy stocks...
AKRX: 30.66 (+0.64), AMCX: 59.35 (+0.58), ICE: 256.89 (+2.93)

3 Beaten-Up Healthcare Stocks: Are They Bargains?
Todd Campbell, The Motley Fool - Motley Fool - Tue Mar 22, 9:26PM CDT
SOURCE: FLICKR USER ELLIOTT BROWN. A sharp sell-off in healthcare stocks has left many investors licking their wounds, but other investors might be licking their chops. With many healthcare stocks trading at their lowest valuation in years, the...
JNJ: 122.85 (+0.34), VRX: 23.25 (-0.24), AKRX: 30.66 (+0.64), DEPO: 18.77 (+0.01)

Transocean and Royal Caribbean slump, Wynn and Staples rise
AP - Tue Mar 22, 3:53PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Tuesday on the New York Stock Exchange and the Nasdaq stock market:
SPLS: 8.85 (+0.28), ESRX: 77.92 (+1.37), RCL: 68.38 (+1.59), RIG: 12.14 (+0.18), AKRX: 30.66 (+0.64), WYNN: 89.75 (+0.79), ODP: 3.29 (+0.03), MFRM: 31.78 (+0.46), MS: 26.37 (+0.68)

Why Akorn, Inc. Is Soaring 39% Today
Todd Campbell, The Motley Fool - Motley Fool - Tue Mar 22, 12:33PM CDT
Image source: Akorn, Inc. What: Following the release of its preliminary fourth-quarter and full-year financials, shares in Akorn  (NASDAQ: AKRX) are rallying 39.05% at 1:00 p.m. Tuesday.  So what: The mid-sized generic pharmaceutical...
AKRX: 30.66 (+0.64)

Look for Shares of Akorn to Potentially Pullback after Yesterday's 36.93% Rise
Comtex SmarTrend(R) - Tue Mar 22, 11:59AM CDT
Akorn (NASDAQ:AKRX) traded in a range yesterday that spanned from a low of $21.78 to a high of $26.26. Yesterday, the shares gained 36.9%, which took the trading range above the 3-day high of $21.23 on volume of 8.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
AKRX: 30.66 (+0.64)

Akorn Receives Expected Additional Delinquency Notice From Nasdaq
GlobeNewswire - Mon Mar 07, 6:00AM CST
Akorn, Inc. (Nasdaq:AKRX) today announced that, as expected, it has received a notice from the Nasdaq Listing Qualifications Staff stating that the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1) because the Company did not timely file its Form 10-K for the year ended December 31, 2015 with the Securities and Exchange Commission (SEC) by February 29, 2016.
AKRX: 30.66 (+0.64)

Akorn Has Returned 20.2% Since SmarTrend Recommendation (AKRX)
Comtex SmarTrend(R) - Fri Feb 05, 10:52AM CST
SmarTrend identified a Downtrend for Akorn (NASDAQ:AKRX) on January 12th, 2016 at $31.33. In approximately 3 weeks, Akorn has returned 20.20% as of today's recent price of $25.00.
AKRX: 30.66 (+0.64)

Shares of AKRX Down 14.6% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Thu Jan 28, 5:41PM CST
SmarTrend identified a Downtrend for Akorn (NASDAQ:AKRX) on January 12th, 2016 at $31.33. In approximately 2 weeks, Akorn has returned 14.55% as of today's recent price of $26.77.
AKRX: 30.66 (+0.64)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

BioVid Debuts AI to Mimic Physician Decision-Making

Updated Category News Views 47

Revolutionizing Understanding: BioVid Mimetics™ Now here's something that's shaking the research tree: BioVid's launching Mimetics™, and it's a big deal. They've come up with AI that can mirror how physicians think and decide. This ain't your run-of-the-mill tech stuff—it's groundbreaking in understanding physician decision-making. The Core: How Do Doctors Really...

Continue Reading
Acqualina Resort's Sustainable Commitment Earns Praise

Updated Category News Views 52

Sustainability at the Heart of Luxury Spotlight's on Acqualina Resort again. The folks there have snagged the 2026 VERIFIED™ Responsible Hospitality badge from Forbes Travel Guide for the third straight year. Means they’re more than just a pretty face down in Miami. This accolade puts them slap bang among the best in sustainable luxury. Forbes doesn’t just hand...

Continue Reading
Divorce Expertise: Obenhaus Adds CDFA Credential

Updated Category News Views 84

Divorce isn't just a legal tangled mess; it's a financial minefield as well. Lindsey Obenhaus from Goranson Bain Ausley has beefed up her credentials with a Certified Divorce Financial Analyst® (CDFA®) designation, lending a sharper edge to her approach in divorce financials. When relationships turn sour, so do wallets, and Obenhaus aims to soften that blow for her...

Continue Reading
Howard Hughes Joins S&P SmallCap 600, Arcosa Out

Updated Category News Views 45

Shakeup in the S&P SmallCap 600 It’s one of those days where something shifts in the market landscape—Howard Hughes Holdings Inc. (NYSE: HHH) is swaggering into the S&P SmallCap 600. Kicking off on October 28, it's got quite the entrance lined up. On the other end, Arcosa Inc. (NYSE: ACA) is making a hasty exit after getting scooped up by CRH plc (NYSE: CRH). For...

Continue Reading
Darden Faces Class Action Over Reimbursement Failures

Updated Category News Views 15

Class Action Puts Darden Restaurants in Legal Hot Seat Darden Restaurants, Inc. is staring down the barrel of a lawsuit that's as fiery as a grill on a Saturday night rush. The legal cavalry from Blumenthal Nordrehaug Bhowmik De Blouw LLP has stormed in with a class action complaint, aiming dead center at Darden for allegedly breaching the California Labor Code. In plain...

Continue Reading
Amy Johnson Steps Up as GDIT President Amid Shifts

Updated Category News Views 68

A New Chapter for GDIT with a Veteran Leader Big shoes to fill? Nah, more like Amy Johnson was made for these shoes. Stepping up as president of General Dynamics Information Technology (GDIT) on November 3, she’s got 27 years of experience under her belt, all from General Dynamics' own backyard. This ain't her first rodeo. From tightrope-walking the perils of defense...

Continue Reading
Taiwan Fuses Ancient TCM with Modern Bio Tech in 2026

Updated Category News Views 40

The Dynamic Fusion of Heritage and Innovation When you think about it, mixing centuries-old herbal wisdom with today's cutting-edge biotech might sound like a plot twist, but that's exactly what's cooking in Taiwan. Over at SupplySide Global 2026 in Las Vegas, Taiwan's got something more than just traditional medicine to flaunt; it's showcasing an impressive fusion of...

Continue Reading
Think Together Marks 20 Years of ASES Impact in CA

Updated Category News Views 64

Hands-on Learning: California's Bright Future Starts Here Who's ever thought a schoolyard's the same after three? Let me tell you, in California, it's staying alive and kicking, thanks to Think Together's whirlwind of celebrations for the After School Education and Safety (ASES) program. We're talking 450 schoolyard shindigs highlighting not just how far expanded learning...

Continue Reading
University of Phoenix Unveils Credit for Prior Learning Advantages

Updated Category News Views 27

Navigating College Credits with Life Experience If you think school is the only place to pick up education that counts, think again. University of Phoenix is challenging this by recognizing the value of the hustle and grind working adults go through. During the recently wrapped-up National Transfer Student Week, Devin Andrews, their VP of Admissions and Evaluation, shed...

Continue Reading
Amgen's IMDELLTRA® Shows Promise in SCLC Battle

Updated Category News Views 142

Breakthrough Results in SCLC Treatment For years, small cell lung cancer (SCLC) has been the unruly beast in the oncology world, defying treatment advances and keeping survival rates stubbornly low. This nasty foe might just have met its match, folks. Amgen (NASDAQ:AMGN) announced results from their Phase 3 DeLLphi-305 trial that show their drug IMDELLTRA®, when teamed...

Continue Reading

Top 5 Most Recently Viewed Articles

VERSES AI Secures Major Contract with Global Investment Firm

Updated Category News Views 183

Strategic Move by VERSES AI VERSES AI Inc. has made an impressive leap in the cognitive computing sector by securing a contract with a leading global investment firm. This partnership is rooted in the recent success of the company's Genius beta program, where initial evaluations highlighted the platform's remarkable capabilities. Enterprise Agreement Details As part of...

Continue Reading
Expected Growth of Agricultural Adjuvants Market to USD 6.2B

Updated Category News Views 143

The Agricultural Adjuvants Market: An Overview The Agricultural Adjuvants Market is witnessing remarkable growth as demand for crop protection products increases. Recent studies estimate that the market, valued at around USD 3.9 billion, is projected to reach approximately USD 6.2 billion by 2034. This translates to a compound annual growth rate (CAGR) of about 4.78% from...

Continue Reading
Understanding CVS Health Inc.'s P/E Ratio in Depth

Updated Category News Views 428

Analyzing the Price-to-Earnings Ratio of CVS Health Inc. In the current trading session, CVS Health Inc. (NYSE: CVS) is trading at a price of $79.86, experiencing a slight decrease of 0.01%. Over the past month, the stock has shown a decline of about 0.99%. However, looking back over the last year, the company's stock has seen a remarkable increase of 44.98%. This...

Continue Reading
Lead the Charge: Edwards Lifesciences Shareholders Unite

Updated Category News Views 138

Understanding the Class Action for Edwards Lifesciences Investors If you are an investor in Edwards Lifesciences Corporation (NYSE: EW), it is crucial to be aware of your rights and options, especially in the wake of substantial losses. Recent developments have opened the door for investors to come together and pursue a collective legal approach toward holding the company...

Continue Reading
Johnson Fistel Investigates Centuri's Stock Price Decline

Updated Category News Views 46

Investigating Centuri Holdings, Inc. Johnson Fistel, LLP, a well-regarded shareholder rights law firm, has initiated an investigation into Centuri Holdings, Inc. (NYSE: CTRI) following a noteworthy decline in the company’s stock price. The firm is examining whether there were any violations of securities laws by the company's executives who may have misrepresented or...

Continue Reading